GROUP SITES OUR RESPONSE TO COVID-19 Menu Integrated Report 2021 Click to view online Click to download Annual Financial Statements 2021 Click to download 2021 Integrated Report ABOUT ASPEN Headquartered in Durban, South Africa, we are a global specialty and branded pharmaceutical company, improving the health of patients across the world through our high quality and affordable medicines. Active at every stage of the value chain, we are uniquely diversiﬁed by geography, product and manufacturing capability. With an acknowledged presence of more than two decades in the pharmaceutical sector, we improve the health of patients in more than 150 countries. The Group’s key business segments are Manufacturing and Commercial Pharmaceuticals comprising Regional Brands and Sterile Focus Brands. GROUP OVERVIEW REGISTER FOR ALERTS Register via Vault for alerts of SENS announcements, reports and event invitations. BOARD OF DIRECTORS INVESTOR OVERVIEW INVESTOR INFORMATION SUSTAINABILITY DOCUMENTS GROUP NEWS Minister Ebrahim Patel opens Aspen’s world class general anaesthetic manufacturing line 25 Oct 2021 Read More Aspen increases revenue from continuing operations by 12% to R37,8 billion 01 Sep 2021 Read More Stephen Saad discusses the J&J vaccine release with eNCA’s Sally Burdett 27 Jul 2021 Read More MORE GROUP NEWS SENS ANNOUNCEMENTS MORE SENS INVESTOR CALENDAR 09 December 2021 Annual General Meeting LATEST RESULTS 2021 INTEGRATED REPORTING YEAR END RESULTS - 30 JUNE 2021 MORE RESULTS REGIONAL OVERVIEWS AFRICA MIDDLE EAST AMERICAS ASIA AUSTRALASIA AFRICA MIDDLE EAST This region represents the single largest revenue contributor in the Commercial Pharmaceuticals segment, with revenues predominantly from Regional Brands. Aspen supplies well-established local brands, as well as internationally recognised medicines across multiple countries in the region, supported by commercial and sales employees. Extensive and differentiated manufacturing capabilities including high potency and hormonal solids, vaccines and other state-of-the-art sterile capabilities exist at one of the Group’s primary manufacturing sites in Gqeberha, South Africa. This primary site is complemented by five regional sites across the continent. Key countries Egypt Kenya Kingdom of Saudi Arabia South Africa Tanzania Number of products launched: 48 (2020: 29) STATISTICS The South African private pharmaceutical sector was valued at R49,8 billion MAT* for the period ended July 2021. In South Africa, four out of the top 15 brands in the private sector were Aspen products. Source: IQVIA, IQVIA Midas 2021 and Market Prognosis Global. South Africa and Middle East and North Africa only. Sub-Saharan Africa (“SSA”) not covered by IQVIA *MAT = Moving annual total © 2021 Aspen Holdings Disclaimer Privacy Statement Aspen PAIA & POPI Manual Standard Terms of purchase of goods or services (STC) Contact details Designed & Produced by Bastion Graphics Cookie consent This website uses cookies that help the website to function and also to track how you interact with our website. But for us to provide the best user experience, enable the specific cookies from Settings, and click on Accept. PreferencesReject AllAccept All